NOT-DA-00-010: SCREENING COMPOUNDS FOR UTILITY AS COCAINE PHARMACOTHERAPIES USING THE RAT SELF-ADMINISTRATION TEST

Department of Health
and Human Services (HHS)

NIH... Turning Discovery Into Health^®



SCREENING COMPOUNDS FOR UTILITY AS COCAINE PHARMACOTHERAPIES USING THE RAT 
SELF-ADMINISTRATION TEST

Release Date:  February 10, 2000

NOTICE:  DA-00-010

RFP AVAILABLE: N01DA-0-8806

National Institute on Drug Abuse

The National Institute on Drug Abuse (NIDA) is soliciting proposals from 
qualified organizations having in-house capabilities to conduct compound 
screening in the rat self-administration test for assessment as potential 
pharmacotherapies for cocaine dependence.
  
Proprietary compounds will be evaluated in established protocols, and the 
resulting data will be utilized by the Cocaine Treatment Discovery Program of the 
NIDA Division of Treatment Research and Development.  Offerors must submit, at 
the time of application, documentation of a current DEA registration for Schedule 
II-V controlled substances and apply for Schedule I registration at the time of 
award.

It is estimated that a 5 year incrementally funded combination completion/term-
type contract with option quantities will be awarded for this procurement.  RFP 
No. N01DA-0-8806 will be available electronically on or about March 13, 2000, and 
may be accessed through the Internet at the following address: (URL: 
http://www.nida.nih.gov/RFP/RFPList.html )

Please note that the RFP for this acquisition will be streamlined to include 
only the Work Statement, Deliverables and Reporting Requirements, Special 
Requirements and Mandatory Qualifications, Technical Evaluation Criteria, and 
other necessary Proposal Preparation Instructions.  All information required 
for submission of an offer will be contained in or accessible through the 
electronic RFP package.  

Response to the RFP will be due on or about April 27, 2000.  Any responsible 
offeror may submit a proposal which will be considered by the Government.  
This advertisement does not commit the Government to award a contract.

Point of Contact: 	Michelle L. Scala, Contract Specialist
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6001 Executive Boulevard
Room 3105, MSC 9543
Bethesda, Maryland 20892-9543
Electronic Mail Address: [email protected]
Telephone: (301) 443-6677
Fax: (301) 443-7595

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices